ESG Matrix |
Materiality |
KPI |
Targets*1 |
FY23 Actual, Progress |
Fiscal Year 2024 Actual, Progress; |
| Environment |
Climate Change*2 |
Scope 1 & 2 CO2 emission reduction |
Carbon neutral by 2040 42% reduction (vs. 2023) by 2030 |
Scope 1: 15,861 tCO2e (base value) Scope 2: 35,304 tCO2 (base value) |
Scope 1 & 2: 50,259 tCO₂e vs. base year: -1.8% (-906 tCO₂e) |
| Scope 3 CO2 emission reduction |
25% reduction (vs. 2023) by 2030 |
Scope 3: 793,687 tCO2 (base value) |
Scope 3: 804,771 tCO2e vs. base year: +1.4%(+11,084 tCO2e) |
| Preservation of Natural Resources |
Percentage of reduction of water withdrawal at production sites / labs on a per revenue basis |
15% reduction (vs. 2023) by 2030 |
1.2 m³/million JPY (base value) |
1.1 m³/million JPY vs. base year: -8% (-0.1 m³/million JPY) |
| Percentage of reduction of packaging material on a per revenue basis |
10% reduction (vs. 2023) by 2030 |
12.8 kg/million JPY (base value) |
10.4 kg/million JPY vs. base year: -19% (-2.4 kg/million JPY) |
| Percentage of reduction of waste generated at production sites / labs on a per revenue basis |
20% reduction (vs. 2023) by 2030 |
17.0 kg/million JPY (base value) |
16.6 kg/million JPY vs. base year: -2% (-0.4 kg/million JPY) |
| Circularity |
Percentage of total waste recycled at production sites / labs (excluding thermal recycling) |
90% by 2030 |
46% |
50% |
| Percentage of recycled content in plastic packaging materials |
10% by 2030 |
0% |
2.2% |
| Social |
Creating Healthcare Innovation that Supports Business Development |
Number of new patent applications (including design and utility models) |
- |
155 |
164 |
| Number of registered patents (including design and utility models) |
- |
4,306 |
4160 |
| Number of new products and services launched |
- |
93 |
55 |
| Sales in growth fields (Advanced Therapy Development, Digital Health, Personalized Testing and Diagnostic) |
86.0 bn JPY by 2025 |
41.0 bn JPY |
39.4 bn JPY |
| Product Excellence |
Number of warning letters issued (e.g., FDA warning letter) |
0 |
0 (achieved) |
0 (achieved) |
| Number of recalls issued |
- |
2 |
3 |
| Enhancement of Supply Chain Management |
Percentage of response rate to PHC Group supplier survey*3 |
95% |
95% (achieved) |
95% (achieved) |
| Expanded Access |
Consolidated sales in emerging and developing markets |
- |
49.3 bn JPY |
56.2 bn JPY |
| People & Culture |
Ratio of gender diversity at manager level or above |
Female ratio: 30% or higher by 2030 |
-*5 |
24.3% |
| Employee Engagement Score: increase from the previous year |
1 point+ improvement vs. PY |
62 YoY -1pt |
67 YoY +5pt (achieved) |
| Enhanced employee learning and skill development |
- |
PHC Academy Skill Database |
PHC Academy (Next Generation) Sikill Databese |
| Governance |
Trengthening Corporate Governance |
Percentage of nationality diversity of the Board of Directors |
- |
25% |
30% |
| Board effectiveness assessment |
1/year |
1 (achieved) |
1 (achieved) |
| Number of meetings with institutional investors and securities analysts |
- |
95 |
106 |
| Risk Management |
Number of Enterprise Risk Management Committee meetings |
2/year |
Kick-off held |
4 (achieved) |
Percentage of employees taking compliance training (e.g., code of conduct, insider trading) |
100% |
100% (achieved) |
100% (achieved) |
| Cybersecurity |
Percentage of employees who participate in information security and data protection training |
100% |
100% (achieved) |
100% (achieved) |
| Biannual vendor security reviews - percentage of critical vendors reviewed*4 |
100% |
100% (achieved) |
100% (achieved) |
| Number of PHC Group Cybersecurity Committee meetings |
4+/year |
4 (achieved) |
4 (achieved) |